CSPC Pharmaceutical Group Ltd (1093.HK)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-CSPC Pharmaceutical Group Announces Drug Registration Approval Of "Paclitaxel For Injection (Albumin-Bound)"
- Tencent, China Mobile to join Hang Seng China Enterprises Index
- BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA
- BRIEF-CSPC Pharmaceutical Group Announces Acquisition Of Stake In Wuhan Yzy Biopharma Co
- BRIEF-CSPC Pharmaceutical Group Says Unit's Listing Application To CSRC Was Accepted